QR code

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab

Immune checkpoint inhibitors, such as pembrolizumab, are revolutionizing therapeutic strategies for different cancer types, including non‐small‐cell lung cancer (NSCLC). However, only a subset of patients benefits from this therapy, and new biomarkers are needed to select better candidates. In this...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Patricia Mondelo‐Macía, Jorge García‐González, Luis León‐Mateos, Urbano Anido, Santiago Aguín, Ihab Abdulkader, María Sánchez‐Ares, Alicia Abalo, Aitor Rodríguez‐Casanova, Ángel Díaz‐Lagares, Ramón Manuel Lago‐Lestón, Laura Muinelo‐Romay, Rafael López‐López, Roberto Díaz‐Peña
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wiley 2021-11-01
Reeks:Molecular Oncology
Onderwerpen:
biomarkers
cfDNA
CTCs
immunotherapy
NSCLC
PD‐L1
Online toegang:https://doi.org/10.1002/1878-0261.13094
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items